ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Surprisingly, although ponatinib represents a promising molecule for patients with BCR-ABL mutations, its mechanism of action has not been extensively studied, more particularly in imatinib-resistant CML cells with no BCR-ABL mutation.